CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Maravai Life Sciences Inc. - MRVI CFD

7.41
1.98%
Market Trading Hours* (UTC) Open now
Closes on Monday at 21:00

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading сonditions
Spread 0.07
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Maravai LifeSciences Holdings Inc ESG Risk Ratings

High Medium Low Negligible

‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 7.56
Open* 7.35
1-Year Change* -55.29%
Day's Range* 7.35 - 7.51
52 wk Range 4.52-16.90
Average Volume (10 days) 1.88M
Average Volume (3 months) 49.85M
Market Cap 1.58B
P/E Ratio 13.31
Shares Outstanding 251.28M
Revenue 419.52M
EPS 0.47
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Feb 20, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Mar 1, 2024 7.56 -0.12 -1.56% 7.68 7.86 7.51
Feb 29, 2024 7.70 -0.33 -4.11% 8.03 8.29 7.62
Feb 28, 2024 7.99 -0.10 -1.24% 8.09 8.38 7.84
Feb 27, 2024 8.23 0.21 2.62% 8.02 8.38 7.76
Feb 26, 2024 8.00 -0.21 -2.56% 8.21 8.76 7.58
Feb 23, 2024 8.34 1.08 14.88% 7.26 8.59 7.19
Feb 22, 2024 5.07 -0.12 -2.31% 5.19 5.19 5.01
Feb 21, 2024 5.24 0.09 1.75% 5.15 5.31 5.12
Feb 20, 2024 5.29 0.15 2.92% 5.14 5.32 5.13
Feb 16, 2024 5.28 -0.06 -1.12% 5.34 5.44 5.22
Feb 15, 2024 5.44 0.33 6.46% 5.11 5.71 5.11
Feb 14, 2024 5.12 -0.03 -0.58% 5.15 5.28 5.08
Feb 13, 2024 5.11 -0.13 -2.48% 5.24 5.32 5.03
Feb 12, 2024 5.46 0.07 1.30% 5.39 5.71 5.38
Feb 9, 2024 5.48 0.08 1.48% 5.40 5.69 5.29
Feb 8, 2024 5.43 0.15 2.84% 5.28 5.46 5.21
Feb 7, 2024 5.43 0.00 0.00% 5.43 5.53 5.35
Feb 6, 2024 5.50 0.41 8.06% 5.09 5.59 5.07
Feb 5, 2024 5.23 0.17 3.36% 5.06 5.40 5.06
Feb 2, 2024 5.21 0.03 0.58% 5.18 5.29 5.11

Maravai Life Sciences Inc. Events

Time (UTC) Country Event
Monday, May 6, 2024

Time (UTC)

10:59

Country

US

Event

Q1 2024 Maravai LifeSciences Holdings Inc Earnings Release
Q1 2024 Maravai LifeSciences Holdings Inc Earnings Release

Forecast

-

Previous

-
Friday, May 17, 2024

Time (UTC)

21:30

Country

US

Event

Maravai LifeSciences Holdings Inc Annual Shareholders Meeting
Maravai LifeSciences Holdings Inc Annual Shareholders Meeting

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 883.001 799.24 284.098 143.14 123.833
Revenue 883.001 799.24 284.098 143.14 123.833
Cost of Revenue, Total 168.957 140.561 79.649 66.849 60.765
Gross Profit 714.044 658.679 204.449 76.291 63.068
Total Operating Expense 308.993 244.595 171.788 119.152 113.019
Selling/General/Admin. Expenses, Total 129.259 100.064 94.245 40.354 33.194
Research & Development 15.569 9.319 1.704 3.627 4.499
Depreciation / Amortization 2.8 5.9 7.6 8 8
Unusual Expense (Income) 0.208 -11.249 -11.41 0 5.622
Other Operating Expenses, Total -7.8 0 0 0.322 0.939
Operating Income 574.008 554.645 112.31 23.988 10.814
Interest Income (Expense), Net Non-Operating -18.076 -30.26 -30.74 -29.959 -27.399
Other, Net -4.46 6.38 0.126 0.118 0.087
Net Income Before Taxes 551.472 530.765 81.696 -5.853 -16.498
Net Income After Taxes 490.663 469.25 78.816 -5.201 -16.915
Minority Interest -270.458 -287.213 13.342 2.4 4.446
Net Income Before Extra. Items 220.205 182.037 92.158 -2.801 -12.469
Net Income 220.205 182.037 92.158 -2.801 -12.469
Total Adjustments to Net Income -15.27 -5.68 -5.259
Income Available to Common Excl. Extra. Items 220.205 182.037 76.888 -8.481 -17.728
Income Available to Common Incl. Extra. Items 220.205 182.037 76.888 -8.481 -17.728
Diluted Net Income 426.276 402.356 76.888 -8.481 -17.728
Diluted Weighted Average Shares 255.323 257.803 257.621 257.621 257.621
Diluted EPS Excluding Extraordinary Items 1.66956 1.56071 0.29845 -0.03292 -0.06881
Dividends per Share - Common Stock Primary Issue 0 0
Diluted Normalized EPS 1.7403 1.52746 0.27165 -0.03292 -0.05463
Dilution Adjustment 206.071 220.319
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 68.914 79.025 204.713 191.263 487.025
Revenue 68.914 79.025 204.713 191.263 487.025
Cost of Revenue, Total 43.273 33.676 53.253 38.176 77.528
Gross Profit 25.641 45.349 151.46 153.087 409.497
Total Operating Expense 80.528 76.492 95.467 74.36 139.166
Selling/General/Admin. Expenses, Total 34.677 37.971 37.203 30.095 59.761
Research & Development 4.194 4.145 4.411 5.389 7.969
Depreciation / Amortization 0.7 0.7 0.6 0.7 1.5
Unusual Expense (Income) 0 0 0 0 0.208
Operating Income -11.614 2.533 109.246 116.903 347.859
Interest Income (Expense), Net Non-Operating -0.231 -5.788 -7.842 -3.136 -7.098
Other, Net -1.519 -1.268 -5.528 -0.004 1.072
Net Income Before Taxes -13.364 -4.523 95.876 113.763 341.833
Net Income After Taxes -11.943 -1.348 87.429 99.653 303.581
Minority Interest 5.402 1.281 -49.795 -55.184 -165.479
Net Income Before Extra. Items -6.541 -0.067 37.634 44.469 138.102
Net Income -6.541 -0.067 37.634 44.469 138.102
Income Available to Common Excl. Extra. Items -6.541 -0.067 37.634 44.469 138.102
Income Available to Common Incl. Extra. Items -6.541 -0.067 37.634 44.469 138.102
Diluted Net Income -6.541 -0.067 75.161 44.487 306.628
Diluted Weighted Average Shares 131.864 131.739 131.626 131.651 193.487
Diluted EPS Excluding Extraordinary Items -0.0496 -0.00051 0.57102 0.33792 1.58475
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.03069 0.02789 0.58965 0.35893 1.63859
Total Adjustments to Net Income
Dilution Adjustment 37.527 0.018 168.526
Other Operating Expenses, Total -2.316 0 0 -7.8
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 847.902 740.039 331.598 60.552 53.802
Cash and Short Term Investments 632.138 551.272 236.184 24.7 21.866
Cash 632.138 551.272 236.184 24.7 21.866
Total Receivables, Net 146.814 117.512 51.218 18.83 15.991
Accounts Receivable - Trade, Net 138.624 117.512 51.218 18.83 15.991
Total Inventory 43.152 51.557 33.301 14.202 14.308
Prepaid Expenses 25.798 19.698 10.895 2.82 1.637
Total Assets 2282.31 1918.28 1270.69 577.796 539.676
Property/Plant/Equipment, Total - Net 116.59 95.427 101.305 94.311 42.578
Property/Plant/Equipment, Total - Gross 136.092 107.959 111.952 102.41 31.492
Accumulated Depreciation, Total -19.502 -12.532 -10.647 -8.099 -4.289
Goodwill, Net 283.668 152.766 224.275 224.275 224.275
Intangibles, Net 216.663 117.571 177.656 197.853 218.127
Other Long Term Assets, Total 817.492 812.473 435.857 0.805 0.894
Total Current Liabilities 110.144 93.777 130.778 29.562 35.919
Accounts Payable 5.991 8.154 8.171 7.478 3.604
Accrued Expenses 50.629 29.34 29.014 16.515 11.147
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 5.44 6 6 2.5 2.5
Other Current Liabilities, Total 48.084 50.283 87.593 3.069 18.668
Total Liabilities 1737.1 1602.78 1182.18 436.4 395.271
Total Long Term Debt 521.997 524.591 584.781 387.702 337.389
Long Term Debt 521.997 524.591 528.614 334.783 335.55
Capital Lease Obligations 0 56.167 52.919 1.839
Deferred Income Tax 0 8.609 14.697 15.856
Minority Interest 360.025 229.862 66.235 3.231 3.611
Other Liabilities, Total 744.931 754.547 391.777 1.208 2.496
Total Equity 545.218 315.499 88.511 141.396 144.405
Common Stock 2.554 2.552 2.576 183.91 182.809
Retained Earnings (Accumulated Deficit) 404.766 184.561 0.854 -42.381 -38.237
Other Equity, Total 0 -0.044 -0.133 -0.167
Total Liabilities & Shareholders’ Equity 2282.31 1918.28 1270.69 577.796 539.676
Total Common Shares Outstanding 255.361 255.157 257.621 257.621 257.621
Additional Paid-In Capital 137.898 128.386 85.125
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 700.865 699.312 765.513 847.902 835.526
Cash and Short Term Investments 579.605 580.176 628.273 632.138 617.446
Cash 579.605 580.176 628.273 632.138 617.446
Total Receivables, Net 49.202 49.219 56.889 146.814 132.224
Accounts Receivable - Trade, Net 45.674 48.987 56.273 138.624 114.069
Total Inventory 49.142 47.402 54.819 43.152 62.424
Prepaid Expenses 22.916 22.515 25.532 25.798 23.432
Total Assets 2267.55 2264.44 2315.39 2282.31 2248.9
Property/Plant/Equipment, Total - Net 216.424 206.633 154.865 116.59 102.538
Goodwill, Net 326.029 326.459 326.569 283.668 283.535
Intangibles, Net 227.856 234.726 241.578 216.663 222.899
Other Long Term Assets, Total 796.379 797.307 826.863 817.492 804.401
Total Current Liabilities 78.253 74.919 124.896 110.144 115.655
Accounts Payable 9.424 6.658 4.784 5.991 9.459
Accrued Expenses 56.042 50.344 66.035 50.629 48.181
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 6.036 6 5.74 5.44 5.44
Other Current Liabilities, Total 6.751 11.917 48.337 48.084 52.575
Total Liabilities 1748.26 1743.87 1793.87 1737.1 1745.14
Total Long Term Debt 551.597 552.572 537.73 521.997 522.824
Long Term Debt 519.52 520.336 521.161 521.997 522.824
Capital Lease Obligations 32.077 32.236 16.569
Deferred Income Tax 6.69 8.512 8.68
Minority Interest 372.987 377.067 379.121 360.025 337.908
Other Liabilities, Total 738.732 730.796 743.444 744.931 768.751
Total Equity 519.294 520.571 521.517 545.218 503.761
Common Stock 2.51 2.51 2.509 2.554 2.552
Additional Paid-In Capital 125.088 119.903 114.309 137.898 134.077
Retained Earnings (Accumulated Deficit) 391.696 398.158 404.699 404.766 367.132
Other Equity, Total
Total Liabilities & Shareholders’ Equity 2267.55 2264.44 2315.39 2282.31 2248.9
Total Common Shares Outstanding 251.039 250.995 250.883 255.361 255.209
Other Current Assets, Total
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line 490.663 469.25 78.816 -5.201 -16.915
Cash From Operating Activities 535.977 368.57 152.187 24.115 -0.186
Cash From Operating Activities 7.566 6.413 5.517 3.81 2.225
Amortization 24.269 18.339 20.32 20.274 20.122
Deferred Taxes 42.318 46.904 -5.464 -1.159 0.317
Non-Cash Items 16.243 4.295 17.105 4.101 9.906
Cash Taxes Paid 23.032 22.473 5.006 -0.802 -0.097
Cash Interest Paid 20.198 27.234 28.916 28.728 25.678
Changes in Working Capital -45.082 -176.631 35.893 2.29 -15.841
Cash From Investing Activities -267.612 105.655 6.068 -17.148 -3.451
Capital Expenditures -17.09 -14.85 -25.408 -17.148 -3.611
Other Investing Cash Flow Items, Total -250.522 120.505 31.476 0 0.16
Cash From Financing Activities -187.499 -159.049 53.212 -4.167 -9.167
Financing Cash Flow Items -184.417 -154.758 -444.983 -1.527 -64.595
Issuance (Retirement) of Debt, Net -5.44 -6 196.924 -2.64 55.428
Foreign Exchange Effects 0 -0.088 0.017 0.034 -0.069
Net Change in Cash 80.866 315.088 211.484 2.834 -12.873
Issuance (Retirement) of Stock, Net 2.358 1.709 301.271
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -1.348 490.663 403.234 303.581 146.86
Cash From Operating Activities 85.074 535.977 436.642 326.583 162.304
Cash From Operating Activities 2.08 7.566 5.604 3.747 1.855
Amortization 6.765 24.269 18.033 11.779 5.527
Deferred Taxes -1.52 42.318 35.307 26.073 13.217
Non-Cash Items 10.756 16.243 3.785 0.769 3.083
Cash Taxes Paid 0.521 23.032 19.581 13.856 0.914
Cash Interest Paid 9.593 20.198 11.416 6.132 1.373
Changes in Working Capital 68.341 -45.082 -29.321 -19.366 -8.238
Cash From Investing Activities -69.73 -267.612 -249.092 -243.245 -241.584
Capital Expenditures -7.868 -17.09 -10.876 -4.409 -2.748
Other Investing Cash Flow Items, Total -61.862 -250.522 -238.216 -238.836 -238.836
Cash From Financing Activities -19.209 -187.499 -121.376 -83.934 -40.523
Financing Cash Flow Items -17.516 -184.417 -119.289 -82.477 -39.889
Issuance (Retirement) of Stock, Net -0.333 2.358 1.993 1.263 0.726
Issuance (Retirement) of Debt, Net -1.36 -5.44 -4.08 -2.72 -1.36
Foreign Exchange Effects 0 0 0 0
Net Change in Cash -3.865 80.866 66.174 -0.596 -119.803
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
GTCR Golder Rauner, LLC Private Equity 16.4345 21681033 0 2023-06-30 LOW
MFS Investment Management Investment Advisor/Hedge Fund 8.2802 10923597 -581604 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 7.9861 10535588 -3628 2023-06-30 LOW
Thrivent Asset Management, LLC Investment Advisor 6.2954 8305132 115334 2023-06-30 LOW
Millennium Management LLC Hedge Fund 5.2879 6975927 6754514 2023-10-20 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.7932 5004116 -62895 2023-06-30 LOW
Mackenzie Financial Corporation Investment Advisor/Hedge Fund 3.7377 4930841 1384455 2023-09-30 LOW
Two Sigma Investments, LP Hedge Fund 3.6721 4844318 1535009 2023-06-30 HIGH
12 West Capital Management, L.P. Hedge Fund 2.5483 3361836 793066 2023-06-30 MED
ClearBridge Investments, LLC Investment Advisor/Hedge Fund 2.3559 3107963 -132200 2023-06-30 LOW
Alyeska Investment Group, L.P. Hedge Fund 1.8767 2475747 691686 2023-06-30 HIGH
Renaissance Technologies LLC Hedge Fund 1.8504 2441175 -751325 2023-06-30 HIGH
Susquehanna International Group, LLP Investment Advisor 1.8489 2439078 1765967 2023-06-30 MED
Ostrum Asset Management Investment Advisor 1.6599 2189817 1236958 2023-06-30 MED
Citi Investment Research (US) Research Firm 1.6578 2187052 -93129 2023-06-30 MED
Pacer Advisors, Inc. Investment Advisor 1.5727 2074794 34601 2023-06-30 MED
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund 1.4837 1957399 929575 2022-12-31 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 1.3906 1834493 -5975 2023-06-30 LOW
Braidwell LP Hedge Fund 1.368 1804700 1804700 2023-06-30 HIGH
Jennison Associates LLC Investment Advisor/Hedge Fund 1.348 1778391 0 2023-06-30 LOW

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Maravai Life Sciences Inc. Company profile

Maravai Life Sciences Inc. provides in vitro diagnostic products, diagnostic laboratory services, and life sciences tools. The company was founded in 2014 and is based in San Diego, California.
Industry: Bio Diagnostics & Testing

10770 Wateridge Circle Suite 200
Suite 200
SAN DIEGO
CALIFORNIA 92121
US

Income Statement

  • Annual
  • Quarterly

News

Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

18:44, 1 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

UK Bank Earnings: What to expect from Lloyds, Barclays and HSBC?

UK banks will be in the spotlight in the week ahead as the European earnings season continues

16:38, 16 February 2024

Is Big Tech behind the apparent bull market rally?

While the Magnificent Seven have dominated market momentum in recent months, it’s not true that they are the sole drivers of the recent rally in equity markets.

16:05, 8 February 2024

US Earnings Week Ahead: Walt Disney, Uber, and Pepsi Co.

The last of the Magnificent Seven have reported, delivering mixed results. Meanwhile, according to FactSet, the S&P 500 is set for negative earnings growth for Q4, with estimates for the next quarter also downgraded.

16:24, 2 February 2024

Bank of England preview: will updated projections show more cuts are expected in 2024?

Markets have no doubt that the BoE will keep its rate unchanged

15:43, 31 January 2024

Meta Platforms Q4 earnings forecast to surge on solid ad revenues

Meta Platforms (META) reports its Q4 results after Wall Street’s closing bell on February 1, 2024. We preview what to expect from the results and analyse the stock’s technicals.

15:33, 31 January 2024

People also watch

Oil - Crude

79.15 Price
-0.420% 1D Chg, %
Long position overnight fee 0.0267%
Short position overnight fee -0.0486%
Overnight fee time 22:00 (UTC)
Spread 0.030

Gold

2,101.92 Price
+0.880% 1D Chg, %
Long position overnight fee -0.0191%
Short position overnight fee 0.0108%
Overnight fee time 22:00 (UTC)
Spread 0.50

XRP/USD

0.67 Price
+5.030% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 22:00 (UTC)
Spread 0.01168

BTC/USD

66,321.30 Price
+5.550% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading